Literature DB >> 21403389

A longitudinal study of behavioral deficits in an AβPP transgenic mouse model of Alzheimer's disease.

Daniel Havas1, Birgit Hutter-Paier, Kiren Ubhi, Edward Rockenstein, Karl Crailsheim, Eliezer Masliah, Manfred Windisch.   

Abstract

Elucidating the age-dependent alterations in transgenic (Tg) mice overexpressing amyloid-β protein precursor (AβPP) is important for understanding the pathogenesis of Alzheimer's disease (AD) and designing experimental therapies. Cross-studies have previously characterized some time-dependent behavioral and pathological alterations in AβPP Tg mice, however, a more comprehensive longitudinal study is needed to fully examine the progressive nature of behavioral deficits in these mice. In order to better understand the age- and gender-dependent progression of behavioral alterations, we performed a longitudinal study wherein Tg mice overexpressing human AβPP751 with the London (V717I) and Swedish (K670M/N671L) mutations under the regulatory control of the neuron specific murine (m)Thy-1 promoter (mThy1-hAβPP751) were behaviorally analyzed at 3 months and then re-tested at 6 and 9 months of age. The results show that there was an age-associated impairment in learning in the water maze task and habituation in the hole-board task. Motor coordination of the mThy1-hAβPP751 Tg mice was well-preserved throughout the investigated life span however, gender-specific deficits were observed in spontaneous activity and thigmotaxis. Neuropathologically, mThy1-hAβPP751 Tg mice displayed a progressive increase in the number of Aβ plaques and mean plaque size in the cortex and hippocampus from 3 to 6 and from 6 to 9 months of age. Taken together, these results indicate that the mThy1-hAβPP751 Tg mice model AD from the early onset of the disease through to later stages, allowing them to be utilized at numerous points during the timeline for drug test designs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403389      PMCID: PMC4944527          DOI: 10.3233/JAD-2011-101866

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  44 in total

Review 1.  Synaptic remodeling during aging and in Alzheimer's disease.

Authors:  Eliezer Masliah; Leslie Crews; Lawrence Hansen
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

Review 2.  Drug discovery in dementia: the role of rodent models.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Nat Rev Drug Discov       Date:  2006-11       Impact factor: 84.694

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42).

Authors:  E Rockenstein; M Mallory; M Mante; A Sisk; E Masliaha
Journal:  J Neurosci Res       Date:  2001-11-15       Impact factor: 4.164

5.  A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease.

Authors:  G Chen; K S Chen; J Knox; J Inglis; A Bernard; S J Martin; A Justice; L McConlogue; D Games; S B Freedman; R G Morris
Journal:  Nature       Date:  2000 Dec 21-28       Impact factor: 49.962

6.  Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein.

Authors:  R D'Hooge; G Nagels; C E Westland; L Mucke; P P De Deyn
Journal:  Neuroreport       Date:  1996-11-04       Impact factor: 1.837

Review 7.  Structural correlates of cognition in dementia: quantification and assessment of synapse change.

Authors:  S T DeKosky; S W Scheff; S D Styren
Journal:  Neurodegeneration       Date:  1996-12

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  The exploratory behaviour of rats in the hole-board apparatus: is head-dipping a valid measure of neophilia?

Authors:  Gillian R Brown; Christopher Nemes
Journal:  Behav Processes       Date:  2008-03-12       Impact factor: 1.777

View more
  20 in total

1.  Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.

Authors:  Markus Mandler; Edward Rockenstein; Kiren Ubhi; Lawrence Hansen; Anthony Adame; Sarah Michael; Douglas Galasko; Radmila Santic; Frank Mattner; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  The Hole-Board Test in Mutant Mice.

Authors:  Robert Lalonde; Catherine Strazielle
Journal:  Behav Genet       Date:  2022-04-28       Impact factor: 2.805

3.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Authors:  Brian Spencer; Paula A Desplats; Cassia R Overk; Elvira Valera-Martin; Robert A Rissman; Chengbiao Wu; Michael Mante; Anthony Adame; Jazmin Florio; Edward Rockenstein; Eliezer Masliah
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

4.  Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

Authors:  Thuy-Vi V Nguyen; Lin Shen; Lilith Vander Griend; Lisa N Quach; Nadia P Belichenko; Nay Saw; Tao Yang; Mehrdad Shamloo; Tony Wyss-Coray; Stephen M Massa; Frank M Longo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 5.  Imaging of cerebrovascular pathology in animal models of Alzheimer's disease.

Authors:  Jan Klohs; Markus Rudin; Derya R Shimshek; Nicolau Beckmann
Journal:  Front Aging Neurosci       Date:  2014-03-13       Impact factor: 5.750

6.  Modulation of the maladaptive stress response to manage diseases of protein folding.

Authors:  Daniela Martino Roth; Darren M Hutt; Jiansong Tong; Marion Bouchecareilh; Ning Wang; Theo Seeley; Johanna F Dekkers; Jeffrey M Beekman; Dan Garza; Lawrence Drew; Eliezer Masliah; Richard I Morimoto; William E Balch
Journal:  PLoS Biol       Date:  2014-11-18       Impact factor: 8.029

7.  L-type calcium channel blockers and substance P induce angiogenesis of cortical vessels associated with beta-amyloid plaques in an Alzheimer mouse model.

Authors:  Nina Daschil; Kathrin M Kniewallner; Gerald J Obermair; Birgit Hutter-Paier; Manfred Windisch; Josef Marksteiner; Christian Humpel
Journal:  Neurobiol Aging       Date:  2014-12-31       Impact factor: 4.673

8.  Non-selective calcium channel blocker bepridil decreases secondary pathology in mice after photothrombotic cortical lesion.

Authors:  Anu Lipsanen; Stefanie Flunkert; Kristina Kuptsova; Mikko Hiltunen; Manfred Windisch; Birgit Hutter-Paier; Jukka Jolkkonen
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

9.  Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function.

Authors:  Mehrdad Faizi; Patrick L Bader; Nay Saw; Thuy-Vi V Nguyen; Simret Beraki; Tony Wyss-Coray; Frank M Longo; Mehrdad Shamloo
Journal:  Brain Behav       Date:  2012-03       Impact factor: 2.708

10.  Neuroinflammation and related neuropathologies in APPSL mice: further value of this in vivo model of Alzheimer's disease.

Authors:  Tina Löffler; Stefanie Flunkert; Daniel Havas; Cornelia Schweinzer; Marni Uger; Manfred Windisch; Ernst Steyrer; Birgit Hutter-Paier
Journal:  J Neuroinflammation       Date:  2014-05-01       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.